Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2005 Dec 7;23(3):297–301. doi: 10.1002/jmv.1890230313

Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine

P N Lelie 1,✉, H W Reesink 1, C J Lucas 1
PMCID: PMC7166500  PMID: 2828525

Abstract

The efficacy of two heating cycles (90 sec at 103°C and 10 hr at 65°C) used during manufacture of a plasma‐derived hepatitis‐B vaccine was validated for the inactivation of 12 virus families. A period of 15 min warming up to 65°C had already completely inactivated representatives of nine virus families, ie, poxvirus (vaccinia), picornavirus (encephalomyocarditis virus), togavirus (sind bis virus), coronavirus (mouse hepatitis virus), orthomyxovirus (influenza virus), rhabdovirus (vesicular stomatitis virus), herpes virus (cytomegalovirus), lentivirus (human immunodeficiency virus), and retrovirus (murine leukemia virus). After prolonged heating at 65°C or heating for 90 sec at 103°C, parvovirus (canine parvovirus) and the phage phiX174 were also completely inactivated. Papovavirus represented by simian virus 40 (SV‐40) was the most heat‐resistant virus evaluated. The infectivity of SV‐40 was reduced by 104 Tissue Culture Infectious Doses (TCID50) per ml after 90 sec at 103°C, but a marginal residual activity (<5 TCID50 per ml) was observed. Subsequent pasteurization for 10 h at 65°C did not further reduce the infectivity of SV‐40. This study shows that the two heat‐inactivation steps used during the production of this vaccine kill a wide variety of viruses that might be present in human blood.

Keywords: hepatitis B vaccine, heat inactivation, viruses, tissue culture infectious doses (TCID50)

References

  1. Coutinho RA, Lelie PN, Albrecht‐van Lent P, Reerink‐Brongers EE, Stoutjesdijk L, Dees PJ, Nivard J, Huisman JG, Reesink HW (1983): Efficacy of a heat‐inactivated hepatitis‐B vaccine in male homosexuals: Outcome of a placebo‐controlled double‐blind trial. British Medical Journal 286: 1305–1308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Desmyter J, Colaert J, de Groote G, Reynders M, Reerink‐Brongers EE, Lelie PN, Dees PJ, Reesink HW, The Leuven Renal Transplantation Collaborative Group (1983): Efficacy of heat‐inactivated hepatitis‐B vaccine in haemodialysis patients and staff: Double‐blind, placebo‐controlled trial. Lancet 2: 1323–1327. [DOI] [PubMed] [Google Scholar]
  3. Gerety RJ, Tabor E (1983): Newly licensed hepatitis‐B vaccine: Known safety and unknown risks. Journal of the American Medical Association 249: 745–746. [PubMed] [Google Scholar]
  4. Lelie PN, Reesink HW, Niessen J, Brotman B, Prince AM (1987): Safety of a plasma‐derived hepatitis‐B vaccine inactivated by two heating cycles:90 seconds at 103 °C and 10 hours pasteurization at 65 °C. I. Inactivation studies of HBV in chimpanzees. Journal of Medical Virology 23: 289–295. [DOI] [PubMed] [Google Scholar]
  5. Martin S, McDougal JS, Loskoski SL (1985): Disinfection and inactivation of the human T‐lymphotropic virus type III: Lymphadenopathy‐associated virus. Journal of Infectious Diseases 152: 400–403. [DOI] [PubMed] [Google Scholar]
  6. McDougal JS, Martin LS, Cart SP, Mozen M, Heldebrant CM, Evatt BL (1985): Inactivation of the acquired immunodeficiency syndrome virus, human T‐lymphotropic virus I JI/lymphadenopathy‐associated virus, with special reference to antihemophilic factor. Journal of Clinical Investigation 76: 875–877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Reerink‐Brongers EE, Reesink HW, Brummelhuis HGJ, Schut BJTH, Dees PJ, Lelie PN, Raap AK, Wilson‐de Stürler LA, van Aken WG, Balner H, van Eerd PMCA, van Schie ThC, Stitz LW, van Steenis B, Feltkamp‐Vroom ThM (1982): Preparation and evaluation of heat‐inactivated HBsAg as a vaccine against hepatitis B In Szmuness W, Alter HJ, Maynard JE. (eds): “Viral Hepatitis.” Philadelphia: Franklin Institute Press, pp 437–449. [Google Scholar]
  8. Resnick L. Veren K, Salahuddin SZ, Tondreau G, Markham PD (1986): Stability and inactivation of HTLV‐III/LAV under clinical and laboratory environments. Journal of the American Medical Association 255: 1887–1891. [PubMed] [Google Scholar]
  9. Rohwer RG (1983): Virus‐like sensitivity of the scrapie agent to heat inactivation. Science 223: 600–602. [DOI] [PubMed] [Google Scholar]
  10. Spire B, Dormont D, Chermann JC (1984a): Inactivation of lymphadenopathyassociated virus by chemical disinfectants. Lancet 2: 899–901. [DOI] [PubMed] [Google Scholar]
  11. Spire B, Barré‐Sinoussi F, Montagnier L, Chermann JC (1984b): Inactivation of lymphadenopathy‐associated virus by heat, gamma rays and ultraviolet light. Lancet 1: 188–189. [DOI] [PubMed] [Google Scholar]
  12. Tabor E, Gerety RJ (1980): Inactivation of an agent of human non‐A, non‐B hepatitis by formalin. Journal of Infectious Diseases 142: 767–770. [DOI] [PubMed] [Google Scholar]
  13. Tabor E, Buynak E, Smallwood LA, Snoy P, (1983): Inactivation of hepatitis‐B virus by three methods: Treatment with pepsin, urea or formalin. Journal of Medical Virology 11: 1–9. [DOI] [PubMed] [Google Scholar]
  14. Wong CW, Ip HMH, Reesink HW, Lelie PN, Reerink‐Brongers EE, Yeung CY, Ma HK (1984): Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis‐B vaccine and hepatitis‐B immunoglobulin. Lancet 1: 921–926. [DOI] [PubMed] [Google Scholar]
  15. World Health Organization (1980): Proposed requirements for hepatitis‐B vaccine. WHO Expert Committee on Biological Standardization, Geneva. WHO/BS/79.1239 pp 1–20.
  16. Yoshizdwa H, Itoh Y, Iwarkiri S, Kitajima K, Tamaka A, Tachibana T, Nakamura T, Myakawa Y, Mayumi M (1982): Nan‐A, non‐B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasma of chimpanzees: Inactivation by formalin and heat. Gasteroenterology 82: 502–506. [PubMed] [Google Scholar]

Articles from Journal of Medical Virology are provided here courtesy of Wiley

RESOURCES